Bhalla R K, Taylor W, Jones A S, Roland N J
Department of Otolaryngology/Head & Neck Surgery, University Hospital Aintree, Liverpool, UK.
Clin Otolaryngol. 2008 Dec;33(6):581-6. doi: 10.1111/j.1749-4486.2008.01837.x.
To investigate inflammation of the pharyngeal mucosa caused by inhaled corticosteroids.
Prospective, cross-sectional, single-blinded study.
University Hospital Aintree, Liverpool, UK.
Fifty adults were recruited from two local general practices and from general ENT clinics at our University hospital. Patients were allocated to one of four groups according to use of inhaled corticosteroids and the presence of adverse local side effects.
Scores achieved on a respiratory symptom questionnaire. Histological markers of inflammation and their correlation with pharyngitis. Statistical modelling included univariate and multivariate analyses, which included multiple linear and logistic regression, and discriminant analysis.
The regular use of inhaled corticosteroids predisposed subjects to hoarseness, weakness of voice, sore throat and throat irritation (P < 0.0001). Pharyngitis was significantly different between the groups (P < 0.0001). Furthermore, those not using an inhaled corticosteroid regularly had little or no clinically apparent pharyngitis, whereas those using an inhaled corticosteroid regularly had significantly higher pharyngitis scores (P = 0.0204). Similarly, weakness of voice (P = 0.0234), hoarseness (P < 0.001) and sore throat (P < 0.001) were also more common in those patients that used an inhaled corticosteroid on a regular basis. To our surprise, however, cellular markers of inflammation did not corroborate the appearances of clinical examination. We found that the five most important discriminators, between those that were using inhaled corticosteroid therapy regularly and those that were not, to be intra-epithelial inflammatory cells (scdf -1.2939); age (scdf 0.8389); use of a spacer device (scdf 0.5456); sore throat (scdf 0.4230) and throat irritation (scdf 0.4015). The groups were significantly different (P < 0.0001). The statistical model used, classified 68% of the cases correctly into their respective groups.
Inhaled corticosteroids predispose to pharyngitis and an inflammatory infiltrate. However, the clinical diagnosis of pharyngitis does not correlate well with cellular inflammatory infiltrate and is therefore, not a reliable measure of underlying inflammation. We advocate caution in the use of pharyngeal erythema as a measure of underlying inflammation.
研究吸入性糖皮质激素引起的咽黏膜炎症。
前瞻性、横断面、单盲研究。
英国利物浦艾恩特里大学医院。
从两个当地普通诊所和我们大学医院的普通耳鼻喉科诊所招募了50名成年人。根据吸入性糖皮质激素的使用情况和局部不良反应的存在,将患者分为四组之一。
呼吸症状问卷得分。炎症的组织学标志物及其与咽炎的相关性。统计建模包括单变量和多变量分析,其中包括多元线性和逻辑回归以及判别分析。
经常使用吸入性糖皮质激素使受试者易出现声音嘶哑、嗓音减弱、喉咙痛和咽喉刺激(P<0.0001)。各组之间咽炎有显著差异(P<0.0001)。此外,不经常使用吸入性糖皮质激素的患者几乎没有或没有明显的临床咽炎,而经常使用吸入性糖皮质激素的患者咽炎得分显著更高(P = 0.0204)。同样,嗓音减弱(P = 0.0234)、声音嘶哑(P<0.001)和喉咙痛(P<0.001)在经常使用吸入性糖皮质激素的患者中也更常见。然而,令我们惊讶的是,炎症的细胞标志物与临床检查结果不一致。我们发现,在经常使用吸入性糖皮质激素治疗的患者和未使用的患者之间,五个最重要的判别因素是上皮内炎性细胞(标准化判别函数值-1.2939);年龄(标准化判别函数值0.8389);使用储物罐装置(标准化判别函数值0.5456);喉咙痛(标准化判别函数值0.4230)和咽喉刺激(标准化判别函数值0.4015)。各组之间有显著差异(P<0.0001)。所使用的统计模型将68%的病例正确分类到各自的组中。
吸入性糖皮质激素易引发咽炎和炎性浸润。然而,咽炎的临床诊断与细胞炎性浸润的相关性不佳,因此,不是潜在炎症的可靠指标。我们主张谨慎使用咽部红斑作为潜在炎症的指标。